adapalene (differin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Adapalene is a topical retinoid primarily used in the treatment of acne and is used (off-label) to treat keratosis pilaris as well as other skin conditions. Galderma currently markets it under the trade names Differin in some countries, and Adaferin in India. Adapalene acts on retinoid receptors. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. Mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.   NCATS

Chemistry

  • SMILES: COC1=C(C=C(C=C1)C2=CC=C3C=C(C=CC3=C2)C(O)=O)C45CC6CC(CC(C6)C4)C5
  • InChIKey: LZCDAPDGXCYOEH-UHFFFAOYSA-N
  • Mol. Mass: 412.5201
  • ALogP: 6.68
  • ChEMBL Molecule:
    adapalene  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0002 - $677.3898
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( adapalene (differin), benzoyl peroxide (clearasil) - other names: epiduo forte, epiduo® forte gel )

Alternative names

6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid | adaferin | adapalen | adapalene | adapalene mixture with benzoyl peroxide | adapaleno | adapalenum | cd0271 | cd-271 | differin | differine | gk530g

Organizations (113)

Research & Development (104)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Acne Vulgaris

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acne Vulgaris ()

Dermatitis, Phototoxic (Phase 3)

Healthy Volunteers (Phase 4)

Inflammation (Phase 1)

Nerve Sheath Neoplasms (Phase 3)

Purpura (Phase 2)

Skin Manifestations (Phase 1)

Warts (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 104

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue